Daiichi Sankyo and AstraZeneca’s lung cancer antibody set for FDA review

cafead

Administrator
Staff member
  • cafead   Feb 20, 2024 at 11:32: AM
via It is shaping up to be a big year for AstraZeneca in lung cancer treatments. Following another approval win for its blockbuster immunotherapy drug Tagrisso (Osimertinib) in non-small cell lung cancer (NSCLC), another drug could be on the way later this year.

article source